Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Clinical trial NCT04933617 · TERMINATED

Trial details

NCT number: NCT04933617
Sponsor: National Cancer Institute (NCI)
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Burkitt Lymphoma High-grade B-cell Lymphoma T-cell/Histocyte-rich Large B-cell Lymphoma Diffuse Large B-Cell Lymphoma (DLBCL)Germinal Center B-cell Type (GCB)

Start date: 2022-03-24
Primary completion: 2023-11-30
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.